Coya Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Coya TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 12.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 24.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 6.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -107.1% betragen.

Wichtige Informationen

-12.9%

Wachstumsrate der Gewinne

-6.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	24.6%
Zukünftige Eigenkapitalrendite	-107.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:COYA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10	-22	-21	-21	1
12/31/2025	8	-22	-15	-15	3
12/31/2024	5	-17	-5	-5	3
3/31/2024	6	-10	-6	-5	N/A
12/31/2023	6	-8	-12	-11	N/A
9/30/2023	N/A	-12	-12	-11	N/A
6/30/2023	N/A	-13	-11	-11	N/A
3/31/2023	N/A	-13	-10	-9	N/A
12/31/2022	N/A	-12	-8	-7	N/A
9/30/2022	N/A	-11	-6	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-6	-5	-5	N/A
12/31/2021	N/A	-5	-4	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: COYA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: COYA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: COYA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: COYADie Einnahmen des Unternehmens (10.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: COYADie Einnahmen des Unternehmens (24.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: COYA wird voraussichtlich in 3 Jahren unrentabel sein.

Coya Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 44%

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 100%

Recent updates

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken